[Editor's note: This article originally appeared in In Vivo, Medtech Insight's sister publication, on 8 November.]
Ten years ago, few scientific papers were being issued on polygenics, a branch of science that assesses an individual’s genetic...
Bringing Polygenics Into Cardiovascular Disease Diagnosis
Effective Tool To Measure Lifetime Risk Of CHD From Polygenics Technology Innovator
GENinCode’s mission as a clinical-genetic diagnostic company is to apply a combination of polygenics, a proprietary bioinformatics platform and AI to risk-assess and prevent cardiovascular disease. The company set a UK precedent in being the first to have a CVD commercial polygenic test implemented in the NHS and keenly awaits another milestone, US 510k clearance in 2024.
